BTIG Reiterates Buy on Nurix Therapeutics, Maintains $30 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $30 price target.
BTIG analyst Jeet Mukherjee reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $30 price target.